Tamoxifen Pharmacogenetics in Asian Breast Cancer Women (Tamoxifen)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01181518 |
Recruitment Status : Unknown
Verified May 2013 by Jae-Gook Shin, Inje University.
Recruitment status was: Recruiting
First Posted : August 13, 2010
Last Update Posted : June 3, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Poisoning by, Adverse Effect of and Underdosing of Tamoxifen |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients |
Study Start Date : | August 2010 |
Estimated Primary Completion Date : | December 2014 |
Estimated Study Completion Date : | December 2015 |

- Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients [ Time Frame: five years ]Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- incident breast cancer patients who underwent surgery
Exclusion Criteria:
- previous cancer history before breast cancer diagnosis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181518
Contact: Ji-Yeob Choi, Ph.D. | 82-51-890-8663 | jychoi@inje.ac.kr |
Korea, Republic of | |
Inje University | Recruiting |
Busan, Korea, Republic of, 614-735 | |
Contact: Ji-Yeob Choi, Ph.D. 82-51-890-8663 jychoi@inje.ac.kr | |
Principal Investigator: Jae-Gook Shin, MD,PhD |
Principal Investigator: | JaeGook Shin, MD,PhD | Inje University |
Responsible Party: | Jae-Gook Shin, Professor, Inje University |
ClinicalTrials.gov Identifier: | NCT01181518 |
Other Study ID Numbers: |
09-140 |
First Posted: | August 13, 2010 Key Record Dates |
Last Update Posted: | June 3, 2013 |
Last Verified: | May 2013 |
Tamoxifen Pharmacogenomics Breast cancer |
Poisoning Chemically-Induced Disorders |